| HOME >> BIOLOGY >> TECHNOLOGY |
Lexicon Pharmaceuticals, Inc.
Selected Financial Data
Three Months Nine Months
Consolidated Statements of Operations Ended Ended
Data September 30, September 30,
(In thousands, except per share data) 2007 2006 2007 2006
(unaudited) (unaudited)
Revenues:
Collaborative research $ 9,712 $ 18,770 $ 34,460 $ 53,427
Subscription and license fees 455 843 1,850 3,305
Total revenues 10,167 19,613 36,310 56,732
Operating expenses:
Research and development, including
stock-based compensation
of $965, $1,101, $3,000,
and $3,355, respectively 24,518 27,010 77,402 81,115
General and administrative,
including stock-based compensation
of $635, $660, $1,830, and $2,011,
respectively 5,091 5,309 15,395 16,276
Total operating expenses 29,609 32,319 92,797 97,391
Loss from operations (19,442) (12,706) (56,487) (40,659)
Interest income 2,166 774 3,811 2,677
Interest expense (694) (817) (2,077) (2,437)
Other expense, net (8) (6) (34) (69)
Loss before noncontrolling
interest in Symphony Icon, Inc. (17,978) (12,755) (54,787) (40,488)
Loss attributable to noncontrolling
interest in Symphony Icon, Inc 3,867 -- 8,170 --
Net loss $(14, 111) $(12,755) $(46,617) $(40,488)
Net loss per common share,
basic and diluted
'/>"/>
| SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |